Mycoplasma amphoriforme is a species closely related to Mycoplasma pneumoniae, thus far with unknown clinical impact. The application of optimized diagnostics, better capable of differentiating between these two micro-organisms, identified a significant patient population positive for M. amphoriforme. The PCR designed by Ling et al. was used on respiratory samples that originally tested positive for M. pneumoniae (n=78), and identified 29 retrospectively as M. amphoriforme. The aim of this study is to describe and compare both groups. The group infected with M. amphoriforme was significantly older and more frequently had a co-infection (19 % vs 62 %), COPD and less fever. This could suggest that M. amphoriforme has opportunistic characteristics.
Mycoplasma amphoriforme was first discovered in 1999 in the United Kingdom in an immunocompromised patient with X-linked agammaglobulinaemia and chronic bronchitis [1] . Since then, only five other papers on M. amphoriforme have been published [2] [3] [4] [5] [6] .
It is closely related to Mycoplasma pneumoniae, a known causative pathogen of many respiratory infections including community-acquired pneumonia. M. pneumoniae is also capable of causing extra-pulmonary (e.g. dermatological, gastro-intestinal or neurological) symptoms [7] . Katsukawa et al. described young patients with an M. amphoriforme infection who developed only a mild fever or did not develop fever at all, in contrast to patients with M. pneumoniae [6] . Gillespie et al. suggested that infection with M. amphoriforme leads to a chronic relapsing and remitting (airway) infection in patients with a primary antibody deficiency, but that it can also lead to an infection in immunocompetent patients [2] . A third study tested 80 patients with suspected lower respiratory tract infection and detected M. amphoriforme in four patients. In a healthy control group of 49 patients, no M. amphoriforme was detected [3] . Whether it can be designated as a primary pathogen is yet to be determined.
A retrospective study was conducted using respiratory samples (bronchoalveolar lavage fluid, sputum or oropharyngeal swabs) collected in a regional hospital between May 2009 and August 2017. A total of 12 375 samples were sent for diagnostics of respiratory infection from several departments (pulmonology, internal medicine, cardiology, ICU, paediatrics). Total nucleic acids were obtained from all respiratory materials using easyMAG (Biomerieux) after pre-treatment with proteinase K (Qiagen). All materials were subjected to multiplexed in-house molecular detection of a complete respiratory panel consisting of 20 of the most common viral pathogens and bacterial pathogens, including M. pneumoniae. For this PCR the oligo sequences described by Tjhie and colleagues were applied [8] . Retrospectively, for all samples positive for Mycoplasma, specific PCRs were applied to differentiate between M. pneumoniae and M. amphoriforme [3, 9] . Validation of the assays and diagnostic testing of the clinical materials included were conducted under ISO15189 accreditation. The analytical performance and clinical validity of the PCRs applied [3, 9] were confirmed using oligonucleotide constructs, clinical materials and proficiency panels (QCMD and Instand). Species specificities, sensitivities and further test characteristics were confirmed both in silico and experimentally.
Of the total of 12 375 samples, 78 (0.63 %) samples tested positive for M. pneumoniae using the PCR method of Thjie et al. and, in most cases, were treated as such. In retrospect, after using the PCR designed by Ling et al., 29 of the 78 samples were identified as M. amphoriforme rather than M. pneumoniae, and 49 samples were confirmed as containing M. pneumoniae by the application of the PCR designed by Hardegger et al. The patient characteristics of these samples were compared to those of the 49 patients in which M. pneumoniae was confirmed (Table 1) . P-values were calculated using the independent samples t-test for the continuous variables and chi square test for ordinal and nominal variables (IBM SPSS Statistics; version 23).
Marked differences were found. The patient group with M. amphoriforme was found to be of greater age than that with M. pneumoniae (65 vs 44 years). The incidence/prevalence of COPD was also found to be more substantial in patients with M. amphoriforme (52 vs 2 %). These findings suggest a difference in the immunocompetence of patients between groups, possibly implying that M. amphoriforme is an opportunistic pathogen. Delayed admission after 16 instead of 9 days of symptoms might indicate a less severe clinical manifestation for M. amphoriforme than for M. pneumoniae. The incidence of co-infections was also higher in the M. amphoriforme group (62 vs 19 %, Table 2 ), which suggests several hypotheses about its pathogenicity. First, M. amphoriforme per se does not cause (significant) symptoms. Secondly, M. amphoriforme is capable of producing symptoms, but more often in patients already infected by other pathogens. And last, M. amphoriforme does not cause symptoms, but is more often present as an innocent bystander in patients with a current infection by another pathogen. The relatively low number of patients experiencing a fever compared to patients with M. pneumoniae is similar to that reported in other studies (19 vs 77 %) [6] .
Certain similarities between the groups were observed. Coughing was present in a large number of patients in both groups (68 vs 90 %). The average CRP was comparable between groups (134 vs 124 mg l À1 ), which might suggest an equal systemic reaction, but this contradicts the differences in the incidence of fever. Only a small number of patients were immunocompromised (17 vs 14 %) in both groups. This might imply that a M. amphoriforme infection is facilitated by an increased local (i.e. pulmonary) susceptibility rather than a systemic immunocompromised state.
To date, only a few case series of M. amphoriforme have been reported. The number of patients with M. amphoriforme in these publications is mostly low (11 or fewer), except for the 45 patients with M. amphoriforme detected in two clinics in the study of Ling et al. [3] . Our study describes the second largest patient group (n=29) of M. amphoriforme found thus far in one clinic, and offers the opportunity to compare the clinical manifestation and response to treatment, since all patients were treated as if they were infected by M. pneumoniae (62 vs 82 % were treated with either a quinolone or a macrolide). No significant difference was found comparing the number of patients who remained symptomatic (coughing, dyspnoea) after 4 weeks. Antibiotic treatment for M. pneumoniae is also likely to be effective in treating M. amphoriforme.
Pereyre et al. tested the susceptibility of three M. amphoriforme strains to antibiotics [4] . The susceptibility for macrolides and tetracyclines of these strains appeared similar to M. pneumoniae strains. They found the minimum inhibitory concentration of ciprofloxacin for M. amphoriforme to be four times lower than that of M. pneumoniae. Gillespie and colleagues found mutations related to macrolide and quinolone resistance in M. amphoriforme strains, similar to that found in other Mycoplasma species [2] . Diagnostic assays that have been developed prior to the next-generation sequencing era may not always differentiate between related species or newly identified species, due to the limited sequence data available at the time. The assay of Tjhie appears not to be specific for M. pneumoniae, when re-analysed using the sequences currently available [8] . The implementation of an optimized PCR, better capable of differentiating between M. amphoriforme and M. pneumoniae, led to the discovery of M. amphoriforme in this patient group.
CONCLUSION
Comparison between the patient groups presenting with either M. pneumoniae or M. amphoriforme suggests that the latter may be a bacterium with opportunistic pathogenicity, based on differences in co-morbidity and co-infection rate. A predisposing factor may be the anatomical and physiological alterations, such as found in patients with COPD.
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